Technetium-99m galactosyl-neoglycoalbumin (99mTc-NGA) is a new hepatocellular receptor imaging ligand Its preparation and preclinical research are reported in this paper. The ligand was synthesized by the chemical coupling and the product was nontoxic and apyrogenic with good stability both in vivo and in vitro. The static images and kinetic data obtained from the liver portal vein ligation group (n = 2), the hepatic necrosis group (n=2) and the control group (n=6) indicate: (1) Tc-NGA imaging can provide excellent hepatic images, and (2) hepatic kinetic data appear to provide a new means for diagnosis of liver diseases.

Forty two patients with coronary artery disease were studied by SPECT and planar methods with dipyridamoloe and rest Tc 99m-MIBI myocardial perfusion imaging. For SPECT, the sensitivity for identification of patients with coronary artery disease was 91%, and for planar methods, the sensitivity was 70%. Comparing dipyridamole with rest images, three kinds of defects were presented (persistent defect, reversible defect and defect in the rest imaging reduced in the dipyridamole imaging). The correlation between SPECT and planar methods was better than between SPECT and ECG. The agreement was 86% for the former and 78% for the latter. There were no serious side effects in the dipyridamole test.